BioSpace News Archive

CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot technology and collaborate in clinical studies.

On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing’s for QuadraMune™, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™ product candidate for pancreatic cancer.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that it received purchase orders from a textile customer totaling $1.6 million to supply molecular taggant to tag textile fibers.

Scientists have created a new machine learning tool that could help healthcare workers to quickly screen and direct the flow of COVID-19 patients arriving at hospitals.

Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, announced the opening of its state-of-the-art manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China.

T.H.A.C SA (The Healthy Aging Company), a biopharmaceutical Company which develops a new class of drugs for the early treatment of type 2 diabetes mellitus (T2DM), announces the acquisition of an international patent submitted by INSERM, Hospitals of Paris, INRA and University of Paris.

Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that it will host a virtual and in-person R&D Day on Tuesday, October 12th, 2021 at 4:00 p.m. CEST/ 10:00 a.m. EDT, being hosted in Paris.

On Thursday, September 30, 2021 , the Barbara Ann Karmanos Cancer Institute will celebrate its 27th annual Partners Event highlighting the importance of cancer research.